logo-01 (3) copy - Copy2.jpg
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
24 juil. 2024 10h00 HE | ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Research Nester Logo.jpg
Pancreatic Cancer Market revenue to reach USD 36 Billion by 2036, says Research Nester
29 nov. 2023 05h30 HE | Research Nester
New York, Nov. 29, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 36...
logo-01 (3) copy - Copy2.jpg
ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
30 mai 2023 10h00 HE | ConSynance Therapeutics
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...
MBX Logos FINAL FULL.jpg
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 08h00 HE | MBX Biosciences, Inc.
CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Logos FINAL FULL.jpg
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
24 janv. 2023 08h00 HE | MBX Biosciences, Inc.
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Logos FINAL FULL.jpg
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 janv. 2023 08h00 HE | MBX Biosciences, Inc.
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Logos FINAL FULL.jpg
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
14 nov. 2022 08h00 HE | MBX Biosciences, Inc.
CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Logos FINAL FULL.jpg
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
05 oct. 2022 09h00 HE | MBX Biosciences, Inc.
CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Logos FINAL FULL.jpg
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
26 juil. 2022 12h00 HE | MBX Biosciences, Inc.
CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders,...
Sm-logo-resized.jpg.png
Human Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.
24 mai 2022 10h39 HE | STRATEGIC MARKET RESEARCH LLP
New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- A Human Microbiome comprises archaea, viruses, bacteria, & eukaryotes which reside within & outside our body system. These organisms...